Technology area: Biotechnology & Pharmaceuticals
15 pending office actions • 11 art units • 15 examiners • 0 of 15 (0%) have an AI response strategy ready • 14 patents granted in the last 365 days
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. has 16 pending office actions in Biotechnology & Pharmaceuticals. The matters span 15 examiners and 11 art units, creating a widely distributed prosecution docket. The difference between pending matters and examiners indicates that at least one examiner handles more than one matter.
BRISTOL, LYNN ANNE is the busiest examiner, with 2 pending matters. That examiner represents a defined coordination point, but the broader docket requires management across many examination records and technical assignments.
Counsel should use centralized tracking for claim scope, cited references, disclosure support, and response status. At the same time, arguments should remain tailored to each examiner and art-unit context. Consistent pharmaceutical terminology can reduce avoidable divergence across related matters.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (13%) |
| §112 only | 4 (27%) |
| Double-patenting + other | 1 (7%) |
| Multi-statute (no §101) | 8 (53%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| COLEMAN, BRENDA LIBBY | 1 | 74.8% | +15.7% |
| HABTE, KAHSAY | 1 | 84.9% | +7.5% |
| CUNNINGCHEN, KATHLEEN MARY | 1 | 62.5% | +60.5% |
| NATARAJAN, MEERA | 1 | 62.6% | +17.9% |
| BORI, IBRAHIM D | 1 | 43.9% | +39.0% |
| MELCHIOR, JAMES RYLAND | 1 | 62.2% | +39.5% |
| PETERS, ALEC JON | 1 | 67.4% | +54.8% |
| BORALSKY, LUKE ALAN | 1 | 66.7% | +44.4% |
| PRIEST, JESSICA MARIE | 1 | — | — |
| REDDIG, PETER J | 1 | 58.0% | +40.2% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18712407 | COMPOUND CONTAINING CYCLOALKYL OR HALOALKYL | HABTE, KAHSAY | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18849031 | CRYSTAL OF FUSED TRICYCLIC DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | COLEMAN, BRENDA LIBBY | — |
| 18690886 | USE OF ANTI-CD40 ANTIBODY | NATARAJAN, MEERA | — |
| 18690198 | COMBINED PHARMACEUTICAL COMPOSITION OF CDK4/6 INHIBITOR AND AROMATASE INHIBITOR | BORI, IBRAHIM D | — |
| 18578850 | COMBINATION DRUG FOR TREATMENT OF GASTRIC CARCINOMA AND/OR ESOPHAGOGASTRIC JUNCTION CANCER | MELCHIOR, JAMES RYLAND | — |
| 18569115 | ANTI-IL-36R ANTIBODY AND USE THEREOF | PETERS, ALEC JON | — |
| 18561553 | COMPOUND USED AS BCR-ABL INHIBITOR | BORALSKY, LUKE ALAN | — |
| 18277608 | PHARMACEUTICAL COMPOSITION CONTAINING ANTI-TSLP ANTIBODY | REDDIG, PETER J | — |
| 18007012 | NOVEL BISPECIFIC ANTI-CD3/CD20 POLYPEPTIDE COMPLEX FORMULATION | BRISTOL, LYNN ANNE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18849031 | CRYSTAL OF FUSED TRICYCLIC DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | COLEMAN, BRENDA LIBBY | — |
| 18703668 | ANTIBODY BINDING TO C-MET AND USE THEREOF | CUNNINGCHEN, KATHLEEN MARY | — |
| 18690886 | USE OF ANTI-CD40 ANTIBODY | NATARAJAN, MEERA | — |
| 18690198 | COMBINED PHARMACEUTICAL COMPOSITION OF CDK4/6 INHIBITOR AND AROMATASE INHIBITOR | BORI, IBRAHIM D | — |
| 18578850 | COMBINATION DRUG FOR TREATMENT OF GASTRIC CARCINOMA AND/OR ESOPHAGOGASTRIC JUNCTION CANCER | MELCHIOR, JAMES RYLAND | — |
| 18569115 | ANTI-IL-36R ANTIBODY AND USE THEREOF | PETERS, ALEC JON | — |
| 18561553 | COMPOUND USED AS BCR-ABL INHIBITOR | BORALSKY, LUKE ALAN | — |
| 18277608 | PHARMACEUTICAL COMPOSITION CONTAINING ANTI-TSLP ANTIBODY | REDDIG, PETER J | — |
| Art Unit | Apps |
|---|---|
| 1624 | 3 |
| 1646 | 2 |
| 1643 | 2 |
| 1629 | 1 |
| 1645 | 1 |
| 1641 | 1 |
| 1642 | 1 |
| 1626 | 1 |
| 1674 | 1 |
| 1647 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18849031 | CRYSTAL OF FUSED TRICYCLIC DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | COLEMAN, BRENDA LIBBY | 1624 | §103§112Other | Non-Final OA | — | Pending | Sep 20, 2024 |
| 18712407 | COMPOUND CONTAINING CYCLOALKYL OR HALOALKYL | HABTE, KAHSAY | 1624 | §112 | Non-Final OA | — | Pending | May 22, 2024 |
| 18703668 | ANTIBODY BINDING TO C-MET AND USE THEREOF | CUNNINGCHEN, KATHLEEN MARY | 1646 | §112Other | Non-Final OA | — | Pending | Apr 29, 2024 |
| 18690886 | USE OF ANTI-CD40 ANTIBODY | NATARAJAN, MEERA | 1643 | §102§103§112 | Non-Final OA | — | Pending | Mar 11, 2024 |
| 18690198 | COMBINED PHARMACEUTICAL COMPOSITION OF CDK4/6 INHIBITOR AND AROMATASE INHIBITOR | BORI, IBRAHIM D | 1629 | §103§112Other | Final Rejection | — | Pending | Mar 07, 2024 |
| 18578850 | COMBINATION DRUG FOR TREATMENT OF GASTRIC CARCINOMA AND/OR ESOPHAGOGASTRIC JUNCTION CANCER | MELCHIOR, JAMES RYLAND | 1645 | §102§103§112 | Non-Final OA | — | Pending | Jan 12, 2024 |
| 18569115 | ANTI-IL-36R ANTIBODY AND USE THEREOF | PETERS, ALEC JON | 1641 | §102§112 | Non-Final OA | — | Pending | Dec 11, 2023 |
| 18561553 | COMPOUND USED AS BCR-ABL INHIBITOR | BORALSKY, LUKE ALAN | 1624 | §103§112 | Non-Final OA | — | Pending | Nov 16, 2023 |
| 18285511 | MULTI-SPECIFIC ANTIBODY TARGETING BCMA | PRIEST, JESSICA MARIE | 1642 | §112DP | Non-Final OA | — | Pending | Oct 04, 2023 |
| 18277608 | PHARMACEUTICAL COMPOSITION CONTAINING ANTI-TSLP ANTIBODY | REDDIG, PETER J | 1646 | §103§112 | Final Rejection | — | Pending | Aug 17, 2023 |
| 18253846 | SALT FORM USED AS CDC7 INHIBITOR AND CRYSTAL FORM THEREOF | CHICKS, ASHLI ARIANA | 1626 | §103 | Non-Final OA | 147d overdue | Pending | May 22, 2023 |
| 18019612 | COMBINED MEDICATION FOR TREATING SOFT TISSUE SARCOMA | KAUFMAN, CLAIRE M | 1674 | §103Other | Non-Final OA | — | Pending | Feb 03, 2023 |
| 18007012 | NOVEL BISPECIFIC ANTI-CD3/CD20 POLYPEPTIDE COMPLEX FORMULATION | BRISTOL, LYNN ANNE | 1643 | §103§112 | Non-Final OA | — | Pending | Jan 26, 2023 |
| 17924613 | ST2 ANTIGEN BINDING PROTEIN | ALLEN, MARIANNE P | 1647 | §112 | Final Rejection | — | Pending | Nov 10, 2022 |
| 17792282 | PHARMACEUTICAL COMPOSITION OF TRICYCLIC PDE3/PDE4 DUAL INHIBITOR COMPOUND | HUANG, GIGI GEORGIANA | 1613 | §112 | Non-Final OA | 14d | Pending | Jul 12, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialChia Tai Tianqing Pharmaceutical Group Co., Ltd. has 15 pending office actions as of October 2026, spread across 11 art units and 15 examiners.
Brenda Libby Coleman has the most, with 1 of Chia Tai Tianqing Pharmaceutical Group Co., Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
